Clinical Trial Update: Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial testing gene-modified lymphocytes with high-dose aldesleukin and a cancer vaccine in progressive or recurrent metastatic kidney cancer and melanom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Cancer
• Melanoma

Drugs mentioned

• Aldesleukin (interleukin-2)
• Gene-modified lymphocytes
• Vaccine therapy

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: Kidney Cancer, Melanoma (Skin) | Phase 2 | Status: TERMINATED | Results posted: 2012-08-14